PHOTO
- AWN Program also helps in cancer patients’ adherence to their treatment protocol with the Immunotherapeutic agent
- MSD will contribute in covering part of the treatment course of enrolled patients in AWN Program in all approved and future-approved indications in UAE as prescribed by specialized oncologists
- In line with MSD’s vision to improve health equity, the program will be implemented in collaboration with charity partners licensed to support patients in UAE
Dubai, United Arab Emirates: The Ministry of Health and Prevention in the UAE, MoHAP, has signed a Memorandum of Understanding (MoU) with MSD, a leading global pharmaceutical company, to support cancer patients in the United Arab Emirates with immunotherapy as part of a landmark program called AWN.
As part of the agreement, MSD will support patients who cannot cover the full cost of the treatment due to limited or lack of health insurance coverage with vials of an immunotherapeutic agent, a humanized monoclonal antibody that helps your fight cancer.1
This immunotherapy is used for treatment of different cancers such as Classical Hodgkin lymphoma, Melanoma, Non-Small Cell Lung Cancer, and other types of solid tumors.1 This treatment is sometimes given alone or combined with other anticancer therapies. The Program will be implemented in collaboration with charity partners who are licensed to aid patients in UAE.
Ashraf Malak, Managing Director, MSD, GCC said, “We are grateful for the opportunity to work with the Ministry of Health and Prevention in launching AWN program. In our mission to provide cancer patients more ways to treat their cancer and enable a better quality of life, we are proud to widen their access to cancer immunotherapy through AWN Program. AWN program will help improve health equity, providing everyone an opportunity to receive the highest standard of care and attain good quality of life. By supporting programs like these, we are working to transform the delivery of cancer care and solving social and environmental barriers to care. Our team is constantly exploring ways to help the greatest number of cancer patients across a broad range of tumor types.”
AWN Program is being implemented in accordance with policies and recommendations of the MoHAP for all approved and future-approved indications of the immunotherapeutic agent in the UAE.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
